Law enforcement across Arkansas found 17 victims of human trafficking after a search of a dozen massage parlors and related ...

Four female hostages are set to be freed by Hamas on Saturday. In exchange, Israel should release around 180 Palestinian ...

New recommendations on how to define obesity would reduce the emphasis on body mass index and take into account health ...

GetSimpli Oral Semaglutide offers a promising solution for those looking to enhance their overall well-being, manage their weight, and improve metabolic health. As an innovative sublingual tablet ...

A first randomized clinical trial shows that semaglutide use in type 1 diabetes is associated with improved glucose management, weight loss and lower insulin requirements. Semaglutide (known by its ...

If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.

Danish multinational pharmaceutical giant Novo Nordisk is the sole owner of semaglutide, the active ingredient in both Ozempic and Wegovy. A month’s supply of Ozempic is close to $1,000 without ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight. At the Cardiometabolic Health Congress ...

Researchers have established that the application of once-weekly semaglutide in patients with type 2 diabetes (T2D) increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION). A ...

The EMA is reviewing Danish studies linking semaglutide to increased NAION risk, following a request from the Danish Medicines Agency. Semaglutide, a GLP-1 receptor agonist, is approved for obesity ...

A July 2024 study published in JAMA Ophthalmology found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a higher risk of a rare eye condition known as "eye stroke," or non ...